Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma
Abstract Background and aims The goal of this study was to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with targeted therapy and PD-(L)1 blockade (triple therapy), either sequentially (SE) or simultaneously (SI), in the treatment of Barcelona Clinic Live...
Saved in:
Main Authors: | Yu-zhe Cao, Jia-yu Pan, Guang-lei Zheng, Chao An, Meng-Xuan Zuo |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2024-11-01
|
Series: | Cancer Immunology, Immunotherapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s00262-024-03872-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
by: Lingling Zhao, et al.
Published: (2025-02-01) -
Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01) -
Single‐Nucleus and Spatial Transcriptome Profiling Delineates the Multicellular Ecosystem in Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy
by: YeXing Huang, et al.
Published: (2025-02-01) -
Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01) -
A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers
by: Qiuyao Zeng, et al.
Published: (2025-01-01)